Who are Pegylated Interferon and Imatinib's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegylated-interferon-and-imatinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pegylated Interferon and Imatinib — Competitive Intelligence Brief

Pegylated Interferon and Imatinib (Pegylated Interferon and Imatinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: interferon alpha (immunomodulator) + tyrosine kinase inhibitor. Area: Oncology.

phase 3 Combination therapy: interferon alpha (immunomodulator) + tyrosine kinase inhibitor Interferon-alpha receptor; BCR-ABL, KIT, PDGFR (imatinib targets) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pegylated Interferon and Imatinib (Pegylated Interferon and Imatinib) — Sheba Medical Center. This combination uses pegylated interferon to enhance immune response against cancer cells while imatinib inhibits tyrosine kinases to block tumor cell proliferation and survival signaling.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pegylated Interferon and Imatinib TARGET	Pegylated Interferon and Imatinib	Sheba Medical Center	phase 3	Combination therapy: interferon alpha (immunomodulator) + tyrosine kinase inhibitor	Interferon-alpha receptor; BCR-ABL, KIT, PDGFR (imatinib targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: interferon alpha (immunomodulator) + tyrosine kinase inhibitor class)

Sheba Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegylated Interferon and Imatinib — Competitive Intelligence Brief. https://druglandscape.com/ci/pegylated-interferon-and-imatinib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab